CDK9 and urinary bladder carcinoma: In this study, we firstly reported a novel lncRNAs termed GAS6‐AS2, promoted proliferation and metastasis of bladder cancer cells via GAS6‐AS2/miR‐298/CDK9 axis, which might serve as a potential biomarker for clinical diagnosis and treatment of bladder cancers.